
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Serotype A Botulinum Toxin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Healis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Healis Therapeutics Shares Phase III Topline Results for CKDB-501A Glabellar Injections
Details : CKDB-501A (serotype A botulinum toxin) is a novel BoNT/A neuromodulator protein. It is being evaluated for the treatment of moderate-to-severe glabellar lines.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : Serotype A Botulinum Toxin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Healis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CKDB-501
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Healis Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Healis Announces Supply Agreement With CKD Bio To Develop CKDB-501
Details : Under the agreement, Healis intends to develop CKDB-501, a neuromodulator Serotype A botulinum toxin (BoNT/A) protein, for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : CKDB-501
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Healis Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CKDB-501A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CKDB-501A is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glabellar Lines.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : CKDB-501A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CKDB-501B
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
Details : CKDB-501B is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glabellar Lines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 23, 2022
Lead Product(s) : CKDB-501B
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CKDB-501A
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity
Details : CKDB-501A is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscle Spasticity.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : CKDB-501A
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CKDB-501A
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
Details : CKDB-501A is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glabellar Lines.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 23, 2022
Lead Product(s) : CKDB-501A
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All